Авторы

  • Azzamov J.A.
  • Kenjayev S.R.

Ключевые слова:

heart failure, empagliflosin, heart failure with preserved ejection fraction, NT-proBNP, left ventricular hypertrophy, echocardiography.

Библиографические ссылки

1. Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Rocca, H. B., Choi, D., Chopra, V., Chuquiure-Valenzuela, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L.,... Packer, M. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/nejmoa2107038

2. Kanagala, P., Arnold, J. R., Singh, A., Chan, D. C. S., Cheng, A. S. H., Khan, J. N., Gulsin, G. S., Yang, J., Zhao, L., Gupta, P., Squire, I. B., Ng, L. L., & McCann, G. P. (2020). Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. PLoS ONE, 15(4), e0232280. https://doi.org/10.1371/journal.pone.0232280

3. Lee, J., Kim, J., Sun, B. J., Jee, S. J., & Park, J. (2021). Effect of Cardiac Rehabilitation on Left Ventricular Diastolic Function in Patients with Acute Myocardial Infarction. Journal of Clinical Medicine, 10(10), 2088. https://doi.org/10.3390/jcm10102088

4. Omar, M., Jensen, J., Ali, M., Frederiksen, P. H., Kistorp, C., Videbæk, L., Poulsen, M. K., Tuxen, C. D., Möller, S., Gustafsson, F., Køber, L., Schou, M., & Møller, J. E. (2021). Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction. JAMA Cardiology, 6(7), 836. https://doi.org/10.1001/jamacardio. 2020.6827

5. Pandey, K. N. (2021). Molecular signaling mechanisms and function of Natriuretic Peptide Receptor-A in the pathophysiology of cardiovascular homeostasis. Frontiers in Physiology, 12, 693099. https://doi.org/10.3389/fphys.2021.693099

6. Shyr, Z. A., Yan, Z., Ustione, A., Egan, E. M., & Remedi, M. S. (2022). SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress. PLoS ONE, 17(2), e0258054. https://doi.org/10.1371/journal.pone.0258054

7. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128. https://doi.org/10.1056/nejmoa1504720